Hepatitis C epidemiology and treatment outcomes in Italy: Impact of the DAA era and the COVID-19 pandemic.
COVID‐19
DAA
HCV
SVR12
high‐risk population
loss to follow‐up
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
27 Jul 2024
27 Jul 2024
Historique:
revised:
18
06
2024
received:
29
02
2024
accepted:
16
07
2024
medline:
29
7
2024
pubmed:
29
7
2024
entrez:
29
7
2024
Statut:
aheadofprint
Résumé
HCV infection poses a global health threat, with significant morbidity and mortality. This study examines HCV trends in a large Italian region from 2015 to 2022, considering demographic changes, evolving clinical profiles, treatment regimens and outcomes, including the impact of the COVID-19 pandemic. This multicentre retrospective study analysed demographics, clinical histories and risk factors in 6882 HCV patients. The study spanned before and after the direct-acting antiviral (DAA) era, and the COVID-19 period, focusing on treatment outcomes (SVR12, non-SVR12 and patients lost to follow-up). Statistical methods included ANOVA, multinomial logistic regression, Kruskal-Wallis test and chi-square analysis, and were conducted adhering to the intention-to-treat (ITT) principle. The cohort, mainly Italian males (average age 58.88), showed Genotype 1 dominance (56.6%) and a high SVR12 rate (97.5%). The pandemic increased follow-up losses, yet SVR12 rates remained stable, influenced by factors like age, gender, cirrhosis and comorbidities. Despite COVID-19 challenges, the region sustained high SVR12 rates in HCV care, emphasising the importance of sustained efforts in HCV care. Continuous screening and targeted interventions in high-risk populations are crucial for achieving WHO elimination targets. The study highlights the resilience of HCV care during the pandemic and provides insights for future public health strategies.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Journal of Viral Hepatitis published by John Wiley & Sons Ltd.
Références
McHutchison JG. Understanding hepatitis C. Am J Manag Care. 2004;10:S21‐S29.
Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529‐538. doi:10.1016/j.jhep.2006.05.013
Cui F, Blach S, Manzengo Mingiedi C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023;8:332‐342. doi:10.1016/S2468-1253(22)00386-7
Hofstraat SHI, Falla AM, Duffell EF, et al. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review. Epidemiol Infect. 2017;145:2873‐2885. doi:10.1017/S0950268817001947
Mason LM, Duffell E, Veldhuijzen IK, Petriti U, Bunge EM, Tavoschi L. Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review. Eur Secur. 2019;24:5‐20. doi:10.2807/1560-7917.ES.2019.24.30.1800614
Kondili LA, Andreoni M, Aghemo A, et al. Prevalence of hepatitis C virus estimates of undiagnosed individuals in different Italian regions: a mathematical modelling approach by route of transmission and fibrosis progression with results up to January 2021. New Microbiol. 2022;45:249‐259.
Andriulli A, Stroffolini T, Mariano A, et al. Declining prevalence and increasing awareness of HCV infection in Italy: a population‐based survey in five metropolitan areas. Eur J Intern Med. 2018;53:79‐84. doi:10.1016/j.ejim.2018.02.015
Mele, A.; Tosti, M.E.; Spada, E.; Mariano, A.; Bianco, E.; SEIEVA collaborative group epidemiology of acute viral hepatitis: twenty years of surveillance through SEIEVA in Italy and a Review of the Literature 2005.
Silvestri C, Bartolacci S, Pepe P, et al. Attempt to calculate the prevalence and features of chronic hepatitis C infection in Tuscany using administrative data. World J Gastroenterol. 2016;22:9829‐9835. doi:10.3748/wjg.v22.i44.9829
Stasi, C.; Silvestri, C.; Pepe, P.; Bartolacci, S.; Voller, F.; Berni, R.; Orsini, C.; Cipriani, F. Epidemiologia Dell'infezione Cronica Da HCV in Toscana 2017. Accessed 18 January, 2024. https://www.ars.toscana.it/eventi/infografiche/890‐2017‐infografica/3858‐epidemiologia‐dell‐infezione‐cronica‐da‐hcv‐in‐toscana.html
WHO Global Health Sector Strategy on Viral Hepatitis. Towards Ending Viral Hepatitis Available online. 2016–2021. Accessed 26 January, 2024 https://www.who.int/publications‐detail‐redirect/WHO‐HIV‐2016.06
WHO. Action Plan for the Health Sector Response to Viral Hepatitis in the WHO European Region. Accessed 26 January, 2024. https://www.who.int/europe/publications/i/item/9789289052870
Ministero della Salute Piano nazionale per la prevenzione delle epatiti virali da virus B e C (PNEV). Accessed on 26 January, 2024 https://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?id=2437&lingua=italiano
Italian Medicine Agency Aggiornamento Epatite C. Accessed on 27 January 2024 https://www.aifa.gov.it/aggiornamento‐epatite‐c
Italian Medicine Agency Redefinition of Treatment Criteria for Chronic HCV Therapy (Determina n. 500/2017).
Regional Council of Tuscany Region Abstract of the Minutes of the Meeting of 09.04.2018. Subject: Project for the Implementation of a Program for the Control of Chronic Hepatitis C in Tuscany (DGR397/2018).
Regional Council of Tuscany Region Launch of a Free Screening Programme to Prevent. Eliminate and Eradicate the Hepatitis C Virus, in Implementation of Art. 25‐Sexies of D.L.n. 162/2019. Approval of the Project.
Barr RG, Wilson SR, Rubens D, Garcia‐Tsao G, Ferraioli G. Update to the Society of Radiologists in ultrasound liver Elastography consensus statement. Radiology. 2020;296:263‐274. doi:10.1148/radiol.2020192437
Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61:1‐32.
Smith BD, Morgan RL, Beckett GA, Falck‐Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945‐1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012;157:817‐822. doi:10.7326/0003-4819-157-9-201211060-00529
Stasi C, Silvestri C, Berni R, et al. Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany. Curr Med Res Opin. 2019;35:661‐666. doi:10.1080/03007995.2018.1482264
Marascio N, Liberto MC, Barreca GS, et al. Update on epidemiology of HCV in Italy: focus on the Calabria region. BMC Infect Dis. 2014;14:S2. doi:10.1186/1471-2334-14-S5-S2
Petruzziello A, Coppola N, Diodato AM, et al. Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples. Intervirology. 2013;56:206‐212. doi:10.1159/000348506
Petruzziello A, Coppola N, Loquercio G, et al. Distribution pattern of hepatitis C virus genotypes and correlation with viral load and risk factors in chronic positive patients. Intervirology. 2014;57:311‐318. doi:10.1159/000363386
Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77‐87. doi:10.1002/hep.27259
Robaeys G, Bielen R, Azar DG, Razavi H, Nevens F. Global genotype distribution of hepatitis C viral infection among people who inject drugs. J Hepatol. 2016;65:1094‐1103. doi:10.1016/j.jhep.2016.07.042
Patel AA, Bui A, Prohl E, et al. Innovations in hepatitis C screening and treatment. Hepatol Commun. 2021;5:371‐386. doi:10.1002/hep4.1646
Aleksanyan Y, Weinman JP. Women, men and COVID‐19. Soc Sci Med. 2022;294:114698. doi:10.1016/j.socscimed.2022.114698
European Centre for Disease Prevention and Control Considerations Relating to Social Distancing Measures in Response to COVID‐19—Second Update. ECDC; 2020.
Zeuzem S, Serfaty L, Vierling J, et al. The safety and efficacy of Elbasvir and Grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol. 2018;53:679‐688. doi:10.1007/s00535-018-1429-3
Zarębska‐Michaluk D, Piekarska A, Jaroszewicz J, et al. Efficacy of 8‐ versus 12‐week treatment with Ledipasvir/Sofosbuvir in chronic hepatitis C patients eligible for 8 week regimen in a real‐world setting. Arch Med Sci. 2019;18:1460‐1466. doi:10.5114/aoms.2019.86569
Holmes JA, Yu M‐L, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy—implication for susceptible individuals. Expert Opin Drug Saf. 2017;16:651‐672. doi:10.1080/14740338.2017.1325869
Calvaruso V, Ferraro D, Licata A, et al. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct‐acting antivirals. J Viral Hepat. 2018;25:72‐79. doi:10.1111/jvh.12754
Scaglione V, Mazzitelli M, Costa C, et al. Virological and clinical outcome of DAA containing regimens in a cohort of patients in Calabria region (southern Italy). Medicina (Kaunas). 2020;56:101. doi:10.3390/medicina56030101
Piecha F, Gänßler J‐M, Ozga A‐K, et al. Treatment and re‐treatment results of HCV patients in the DAA era. PLoS One. 2020;15:e0232773. doi:10.1371/journal.pone.0232773
Hashim A, Almahdi F, Albaba EA, et al. Efficacy of DAAs in the treatment of chronic HCV: real‐world data from the private health‐care sector of the Kingdom of Saudi Arabia. J Epidemiol Glob Health. 2020;10:178‐183. doi:10.2991/jegh.k.200117.002
Schmitt A, Günther R, Mauss S, et al. Treatment‐failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy—data from the German hepatitis C registry (DHC‐R). Z Gastroenterol. 2020;58:341‐351. doi:10.1055/a-1068-3056
Howe AYM, Rodrigo C, Cunningham EB, et al. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct‐acting antivirals. JHEP Rep. 2022;4:100462. doi:10.1016/j.jhepr.2022.100462
Bischoff J, Mauss S, Cordes C, et al. Rates of sustained Virological response 12 weeks after the scheduled end of direct‐acting antiviral (DAA)‐based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? HIV Med. 2018;19:299‐307. doi:10.1111/hiv.12579
Vergara‐Samur H, Martínez‐Vernaza S, De la Hoz A, et al. Comparative outcomes of direct‐acting antiviral treatment in patients with HIV‐hepatitis C Co‐infection: insights from a single center experience in Colombia. Infez Med. 2023;31:374‐383. doi:10.53854/liim-3103-11
Lodi S, Klein M, Rauch A, et al. Sustained Virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C Co‐infection. J Int AIDS Soc. 2022;25:e26048. doi:10.1002/jia2.26048
Sacks‐Davis R, van Santen DK, Boyd A, et al. Changes in incidence of hepatitis C virus reinfection and access to direct‐acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies. Lancet HIV. 2024;S2352–3018(23):267‐269. doi:10.1016/S2352-3018(23)00267-9
Blach S, Kondili LA, Aghemo A, et al. Impact of COVID‐19 on global HCV elimination efforts. J Hepatol. 2021;74:31‐36. doi:10.1016/j.jhep.2020.07.042
Arnetz BB, Goetz C, vanSchagen J, Baer W, Smith S, Arnetz JE. Patient‐reported factors associated with avoidance of in‐person care during the COVID‐19 pandemic: results from a National Survey. PLoS One. 2022;17:e0272609. doi:10.1371/journal.pone.0272609
Pawlotsky J‐M, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461‐511. doi:10.1016/j.jhep.2018.03.026
van Dijk M, Drenth JPH. HepNed study group loss to follow‐up in the hepatitis C care Cascade: a substantial problem but opportunity for micro‐elimination. J Viral Hepat. 2020;27:1270‐1283. doi:10.1111/jvh.13399
Lindqvist K, Thorin Z, Kåberg M. Real‐world hepatitis C treatment outcomes and reinfections among people who inject drugs at a needle and syringe program in Stockholm. Sweden Harm Reduct J. 2023;20:72. doi:10.1186/s12954-023-00801-1